Who Vivo Capital invests alongside: EcoR1 Capital, Norwest Venture Partners, Polaris Partners — mapped across 12 portfolio companies in 1 sectors and 5 cities.
Vivo Capital accounts for 54 tracked companies with verified cap-table data, 54 of which disclose round sizes totalling $7.9B. The median disclosed raise is $127M, and the largest is Gracell Biotechnologies at $520M, ahead of Tebra ($387M) and Avistone Pharmaceuticals ($340M).
The names that recur most often on these co-invested cap tables are Vivo Capital (54 companies), Logos Capital (11 companies), Cormorant Asset Management (10 companies), OrbiMed (9 companies), RA Capital Management (9 companies), Lilly Asia Ventures (7 companies). By latest disclosed round, the market skews Series B (15), Series A (9), Series C (8), IPO (5).
Companies tracked: 54
Disclosed funding total: $7.9B across 54 companies
Median disclosed raise: $127M
Largest raise: Gracell Biotechnologies — $520M
Stage mix: Series B 15 · Series A 9 · Series C 8 · IPO 5
